Navigation Links
Sylentis Completes Phase I Trial with SYL040012 to Treat Elevated Intraocular Pressure and Glaucoma
Date:7/6/2010

MADRID, July 6 /PRNewswire/ -- Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

This is the first product based on RNAi technology to be developed clinically in Spain.

The trial received approval from the Spanish Medicines and Health Products Agency in June 2009, and was conducted by specialists in pharmacology and ophthalmology at Navarra University Clinic.

The trial's endpoint was to determine the tolerance and safety of SYL040012 ophthalmic drops; it was administered to 30 healthy volunteers aged 18 to 33. Patients showed excellent local and systemic tolerance to SYL040012, leading to very positive trial results. Sylentis plans to commence a Phase I/II clinical trial in patients with elevated intraocular pressure as soon as possible.

About SYL040012

In preclinical trials with SYL040012, the siRNAs administered topically to treat ocular hypertension associated with open angle glaucoma have proven effective both in vitro and in vivo. In those trials, SYL040012 effectively prevented the increase in intraocular pressure induced in the ocular hypertension model that was used. Ocular tolerance studies have shown excellent local and systemic tolerance to the administration of SYL040012 in much larger doses than required for therapeutic effectiveness.

About Sylentis

Founded in
'/>"/>

SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
2. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
3. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
4. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
5. AutoImmune Inc. Files Certificate of Dissolution and Completes Sale of Colloral® Business; Trading of Common Stock to Cease After June 30, 2010
6. Patient Safety Technologies Completes $6.0 Million Equity Financing
7. CardioMEMS Completes CHAMPION Clinical Trial Study
8. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
9. CareFusion Completes Medegen Acquisition
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  The law firm McElroy, Deutsch, Mulvaney ... will serve as host for "Show Me the ... of Healthcare Reform," a one-day conference scheduled for ... reimbursement, compliance and enforcement in a marketplace re-shaped ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... 2014 Sutro Biopharma, a biopharmaceutical company developing ... division of Merck KGaA, Darmstadt, Germany ... the United States and Canada ... to develop antibody drug conjugates (ADCs). ADCs are composed ... antibody is thought to specifically target and deliver the ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... 13, 2011 ULURU Inc. (NYSE AMEX: ... of intent with Melmed Holdings AG, a company based in Switzerland, ... terms of the agreement ULURU will license the European Union rights ... Altrazeal® in the European Union. In exchange for the license ULURU ...
... Mass., Oct. 12, 2011 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced plans to release its financial ... on Thursday, November 3, 2011 before the opening of ... NxStage will also host a conference call at 9:00 ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3NxStage® to Report Third Quarter Fiscal 2011 Financial Results 2
(Date:9/17/2014)... (PRWEB) September 18, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has released its ... In addition, the firm has launched a big sale ... are now available at deeply discounted rates, from 15 ... that the company insists on using comfortable to wear ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
(Date:9/17/2014)... According to an August 5, ... “Adverse Events Associated with Use of Enhancement Medical's ... use of Expression, a hyaluronic acid product, for ... including discoloration, lumps, bruising, nodules, and swelling. ... cosmetic use include Restylane , Juvéderm, Perlane, ...
(Date:9/17/2014)... 2014 Final Cut Pro X plugin developers ... from Pixel Film Studios. , “ProBlue 5k is a compilation ... good to epic,” said Christina Austin, CEO of Pixel Film ... is a definite game changer.” , ProBlue 5k is the ... filmmaker ! This footage compilation of over 100 anamorphic ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy ... and get the answer by reading Per Wickstrom’s latest blog ... a business plan and a business strategy are both strategic ... “The way I view it is that a business plan ... part two.” , According to the blog post, a ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2
... ... , ... April 19, 2010 -- ORCS Web Inc., a specialist in Microsoft Windows-based internet hosting ... newly released ASP .NET 4.0 has been made available on all of their ...
... ... to age gracefully and maintain healthy skin? Here are 35 articles that cover the full ... any age, makeup tips for mature skin and the details on effective ingredients. , ... (PRWEB) April 19, 2010 -- Aging ...
... ... Institute is penetrating major metropolitan areas with its high-demand, proactive medical approach that optimizes ... ... Medical Institute , global age management medicine leader, is meeting the healthy aging boom ...
... ... the 40th Earth Day. The first Earth Day was held in 1970 and is widely seen ... ... join the worldwide community in celebrating the 40th Earth Day. The first Earth Day was held ...
... at the Medical College of Wisconsin and Children,s Hospital ... have found that many metropolitan Milwaukee child care directors ... Andrew N. Hashikawa, M.D., and colleagues surveyed 305 child ... directors followed national guidelines from the American Academy of ...
... Treatment may be used one day as part of cancer-fighting ... April 18 (HealthDay News) -- A new study in mice ... cells could become a target for cancer vaccines. , A ... transcription) of genetic material from the DNA to messenger RNA. ...
Cached Medicine News:Health News:ORCS Web, Inc Supports ASP .NET 4.0 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 3Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 4Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 2Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 3Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 4Health News:Ecco Bella, A Natural Beauty and Skin Care Company, Celebrates Earth Day 2010 2Health News:Day care dilemma: When 'sick' children are unnecessarily sent home 2Health News:Vaccine Stops Tumor Spread in Mice 2
Sealing tape, white Rayon, breathable, NS...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Thermal Seal, Clear, Bulk...
Medicine Products: